

# Europe's Beating Cancer Plan

Call for proposals on Personalised Cancer Medicine – (CR-g-24-99)

**Vittoria Carraro, Policy Officer  
DG Health and Food Safety**

**#EUCancerPlan #HealthUnion**





## Flagship 6. 'Cancer Diagnostic and Treatment for All':

- improve access to innovative therapies and optimise cancer diagnosis and treatments;
- use the 'next generation sequencing' technology;
- reduce unequal access to personalised medicine in cancer care greatly benefitting patients.

# ENSURING HIGH STANDARDS IN CANCER CARE



## 2024 EU4Health Work Programme call

- CR-g-24-99 (Call for proposals on personalised cancer medicine):
  - ❑ **Type of applicants targeted** - Academia and education establishments, research institutes, hospitals, public authorities, expert networks, civil society organisations associations, foundations, NGOs and similar entitie;
  - ❑ **Budget - EUR 3 000 000;**
  - ❑ **Supporting CR-g-24-41 - Joint Action on Personalised Cancer Medicine.**

# For context: (Personalised Cancer Medicine JA)



## Objectives of CR-g-24-41 (Personalised Cancer Medicine JA)

- **Strengthen the PCM network within the Union**

### Examples of eligible actions:

- develop guidance tools, recommendations and protocols;
- upscaling of the EU Cancer and Public Health Genomics Platform;
- education and training for health professionals;
- establishing strategies for the implementation of telegenetics and remote genetic counselling;
- information campaigns and stakeholder engagement activities.

# CR-g-24-99 (Personalised Cancer Medicine)



## Objectives:

**The aim of the action is to complement the implementation of the ‘Joint Action on Personalized Cancer Medicine’.**

It will make use of materials developed under the ‘Cancer Diagnostic and Treatment for All’ initiative projects and other relevant European Commission projects:\*

- ‘Genomic for Public Health’ (PCM4EU); EU Cancer and Public Health Genomics platform project (CAN.HEAL); and the project for improved diagnostics and survival for all children with Acute Myeloid Leukaemia (CHIP-AML22).
- Make use of the guidelines, protocols and best practices e.g., developed under 1+ Million Genomes Initiative, EOSC4Cancer; and Partnership on Transforming Health and Care Systems(THCS). Innovative Health Initiative (IHI) projects also eligible.

\* JRC created a cancer projects tools to support this [https://knowledge4policy.ec.europa.eu/cancer\\_en](https://knowledge4policy.ec.europa.eu/cancer_en)

# CR-g-24-99 (Personalised Cancer Medicine)



## Examples of actions that can be funded:

- the implementation of **targeted projects involving civil society organisations and industry** complementing the Member States' actions in **the Personalised cancer medicine JA**,
  - the production of public health guidelines concerning personalised cancer medicine, genomic testing/screening and metastatic cancer management;
  - patients and caregivers consultations, and other actions that can benefit citizens directly;
  - preparation and roll out of innovative practices;
  - support capacity building actions such as training and twinning, health communication or health literacy.

Activities should also include an equity dimension.



## Coordination with Joint Action on Personalized Medicine:

- Collaboration and communication mechanisms with Joint Action on Personalised Cancer Medicine should be described in the proposal (may be further detailed in grant agreement preparation);
- Can include a specific WP on collaboration with the Joint Action;
- Reports on progress activities, challenges and alignment with Joint Action on Personalised Cancer Medicine;
- Sustainability report for project results and established practices, including lessons learned;
- The visual identity and communication materials aligned with Joint Action on Personalised Cancer Medicine.



## Expected Results And Impact:

- benefit cancer patients accessing personalised cancer medicine services, in turn reduce the burden of cancer in the Member States.

## **Initiatives to complement Member States' efforts**

- support for the development of public health guidelines (e.g., personalised cancer medicine, genomic testing/screening and metastatic cancer management);
- support for the preparation and roll out of new policy approaches;
- participation in the pilot testing of innovative practices;
- development of capacity building actions such as training and twinning.



# Thank you

Follow us:

@EU\_Health

#EUCancerPlan